RxDoctor Payments Data

Cynthia Chiu, MD

Ophthalmology · Oakland, CANPI 1306852629

Payments from drug & device makers

$12,912in general payments, 2019–2025

Across 241 payments — averaging $53.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$9K
  • AbbVie$737
  • Sun Pharmaceutical Industries Inc.$517
  • Oyster Point Pharma, Inc.$452
  • Novartis$400
  • Mallinckrodt Hospital Products Inc.$340
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$7,13455%
  • Food & beverage$5,76045%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,912 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$441,533
Medicare patients
1,082
Services billed
3,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine99$56,590
RestasisCyclosporine38$47,113
LumiganBimatoprost51$28,936
XiidraLifitegrast20$27,828
CequaCyclosporine16$16,103
RocklatanNetarsudil Mesylat/Latanoprost18$12,547
TyrvayaVarenicline Tartrate11$11,610
Prednisolone Acetate205$9,747
Latanoprost428$6,939
Difluprednate33$5,658
Alphagan PBrimonidine Tartrate11$5,412
Ketorolac Tromethamine199$5,014
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$3,787
MoxifloxacinMoxifloxacin Hcl188$3,698
Brinzolamide19$3,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$737$81,461100 claims
Bausch & Lomb Americas Inc.Xiidra$165$27,82820 claims
Sun Pharmaceutical Industries Inc.Cequa$517$16,10316 claims
Aerie Pharmaceuticals, Inc.Rocklatan$155$12,54718 claims
Oyster Point Pharma, Inc.Tyrvaya$452$11,61011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →